专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO1992016211A1 NEW USE OF DIPHENYLBUTYL-PIPERAZINECARBOXAMIDES IN THE TREATMENT OF SUBSTANCE DISORDERS 审中-公开
标题翻译：二苯乙烯 - 哌嗪甲酰胺在治疗物质障碍方面的新用途
公开(公告)号：WO1992016211A1
公开(公告)日：1992-10-01
申请号：PCT/SE1992000182
申请日：1992-03-23
申请人： KABI PHARMACIA AB , BJÖRK, Anders , CHRISTENSSON, Erik
发明人： KABI PHARMACIA AB
IPC分类号： A61K31/495
CPC分类号： C07D295/215 , A61K31/495 , Y10S514/811 , Y10S514/813
摘要： New use of certain diphenylbutyl-piperazinecarboxamides, especially amperozide, 4-[4,4-bis(4-fluorophenyl)butyl]-N-ethyl-1-piperazinecarboxamide, and salts thereof, in the treatment of substance abuse disorders. More particularly, this treatment relates to the amelioration of withdrawal symptoms and to modifying drug-seeking behaviour.
摘要翻译：某些二苯基丁基 - 哌嗪甲酰胺，特别是安非他酮，4- [4,4-双（4-氟苯基）丁基] -N-乙基-1-哌嗪甲酰胺及其盐的新用途用于治疗物质滥用障碍。更具体地说，这种治疗涉及戒断症状的改善和改善药物寻求行为。

2. 发明申请

WO1993020821A1 AGENTS FOR TREATING SUBSTANCE ABUSE DISORDERS 审中-公开
标题翻译：用于治疗物质滥用症状的药剂
公开(公告)号：WO1993020821A1
公开(公告)日：1993-10-28
申请号：PCT/SE1993000339
申请日：1993-04-19
申请人： KABI PHARMACIA AB , BJÖRK, Anders , ANDERSSON, Gunnar
发明人： KABI PHARMACIA AB
IPC分类号： A61K31/495
CPC分类号： A61K31/495 , Y10S514/81 , Y10S514/811 , Y10S514/812 , Y10S514/813
摘要： A method for relief or prevention of a withdrawal syndrome resulting from addiction to a drug or substance of abuse and/or for the suppression of dependence on drugs or substances of abuse which comprises administering an effective amount of bisphenylalkylpiperazines of formula (I) and the pharmaceutically acceptable acid addition salts thereof.
摘要翻译：一种缓解或预防由药物或滥用物质成瘾引起的戒断综合征和/或用于抑制对药物或滥用物质的依赖的方法，其包括给予有效量的式（I）的双苯基烷基哌嗪和药学上其可接受的酸加成盐。

3. 发明申请

WO1994000434A1 NOVEL NICOTINIC ACID ESTERS 审中-公开
标题翻译：新颖的酸甜味
公开(公告)号：WO1994000434A1
公开(公告)日：1994-01-06
申请号：PCT/SE1993000565
申请日：1993-06-23
申请人： KABI PHARMACIA AB , LUNDSTEDT, Torbjörn , ABRAMO, Lisbeth , BJÖRK, Anders , PETTERSSON, Göran , ANDERSSON, Gunnar , NORDVI, Curt , CHANG WU, Jin , LUDWIG, Catarina , SEIFERT, Elisabeth , NILSSON, Arne
发明人： KABI PHARMACIA AB
IPC分类号： C07D213/80
CPC分类号： C07D213/80
摘要： The present invention concerns novel compounds of formula (II) wherein R is selected from saturated or unsaturated alkyls, saturated or unsaturated cycloalkyls, heterocyclic compounds or from (a) or (b) wherein G is carbon or nitrogen; m is 0-10; wherein R1, R2 and R3 are the same or different and selected from hydrogen, halogen, alkyl having 1 to 5 carbon atoms, electron donor groups such as alkoxy having 1-5 carbon atoms or hydroxy, electron acceptor groups selected from cyano, nitro, trifluoroalkyl and the pharmacologically active salts thereof. The new compounds can be used for treating disorder in the central nervous system.
摘要翻译：本发明涉及式（II）的新型化合物，其中R选自饱和或不饱和的烷基，饱和或不饱和环烷基，杂环化合物或（a）或（b）其中G是碳或氮; m为0-10; 其中R1，R2和R3相同或不同，选自氢，卤素，具有1-5个碳原子的烷基，电子给体基团如具有1-5个碳原子的烷氧基或羟基，选自氰基，硝基，三氟烷基及其药理学活性盐。新化合物可用于治疗中枢神经系统疾病。

4. 发明申请

WO1994012532A1 NEW OLIGOPEPTIDES WITH AFFINITY TO OPIOID RECEPTORS 审中-公开
标题翻译：具有对阿片受体的亲和力的新的寡核苷酸
公开(公告)号：WO1994012532A1
公开(公告)日：1994-06-09
申请号：PCT/SE1993000986
申请日：1993-11-18
申请人： KABI PHARMACIA AB , FHÖLENHAG, Karin, Ingeborg , FRYKLUND, Linda , LARSSON, Bo, Christer , NYBERG, Fred, Jarl , WESTIN-SJÖDAHL, Gertrud, Elisabeth , LUNDIN, Ronny
发明人： KABI PHARMACIA AB
IPC分类号： C07K07/12
CPC分类号： C07K14/61 , A61K38/00 , C07K5/1016 , C07K14/665
摘要： Disclosed are novel oligopeptides with opioid receptor affinity which are straight or cyclic pentapeptides with the primary sequence backbone Tyr-X-Phe-Leu-Z, where X and Z denote amino acids or amino acid derivatives and/or analogues and where X and Z can be covalently coupled to provide a heterocyclic structure wherein Z is chosen among Cys, Glu, Gln or amino derivatives of Glu and Gln; X will be chosen among the amino acids or amino acid analogues Ser, Gly, Pro, AMCA, D-Ala, D- or L-ornithine, D- or L-2,4-diaminobutyric acid, D- or L-Lys and D- or L-Cys. Also disclosed are pharmaceutical preparations comprising said oligopeptides, which are potentially useful as analgesics for alleviating pain, for the treatment of depressions and for increasing the comfort of individuals suffering from extraordinary stress or shock.
摘要翻译：公开了具有阿片受体亲和力的新型寡肽，其是具有一级序列主链Tyr-X-Phe-Leu-Z的直链或环状五肽，其中X和Z表示氨基酸或氨基酸衍生物和/或类似物，并且其中X和Z可以共价偶联以提供杂环结构，其中Z选自Glu和Gln的Cys，Glu，Gln或氨基衍生物; X选自氨基酸或氨基酸类似物Ser，Gly，Pro，AMCA，D-Ala，D-或L-鸟氨酸，D-或L-2,4-二氨基丁酸，D-或L-Lys和 D-或L-Cys。还公开了包含所述寡肽的药物制剂，其可潜在地用作用于缓解疼痛的止痛剂，用于治疗沮丧并增加患有非凡压力或休克的个体的舒适性。

5. 发明申请

WO1994007920A1 DNA ENCODING A PROSTAGLANDIN RECEPTOR, A HOST CELL TRANSFORMED THEREWITH AND AN EXPRESSION PRODUCT THEREOF 审中-公开
标题翻译：编码前列腺素受体的DNA，其转化的宿主细胞及其表达产物
公开(公告)号：WO1994007920A1
公开(公告)日：1994-04-14
申请号：PCT/SE1993000789
申请日：1993-10-01
申请人： KABI PHARMACIA AB , LAKE, Staffan , STJERNSCHANTZ, Johan
发明人： KABI PHARMACIA AB
IPC分类号： C07K15/06
CPC分类号： C07K14/705
摘要： Molecular cloning and expression of a prostaglandin F2 alpha receptor which is linked to the signal transduction pathways via guanine nucleotide binding regulatory (G) proteins and measured by, for example, cAMP, IP3 or intracellular calcium. By constructing cell lines that express a prostaglandin F2 alpha receptor, the affinities and efficacies of agonist and antagonist drugs with the receptor can be assessed. A recombinant DNA construct includes a vector and a DNA fragment encoding a prostaglandin F2 alpha receptor. A host cell is transformed with a recombinant DNA construct, so that the DNA-fragment is expressed and a prostaglandin F2 alpha receptor is produced. Suitable host system includes eukaryotic and prokaryotic cells, especially mammalian cells such as rat or human. Additionally, for diagnostic purposes, antibodies to a prostaglandin F2 alpha receptor can be prepared by producing all or a portion of the receptor protein and injecting these into various types of mammals. Using the resulting antibodies, expression of an F2 alpha receptor cDNA, i.e. receptor protein in tissue and cells can be measured.
摘要翻译：通过鸟嘌呤核苷酸结合调节（G）蛋白与通过例如cAMP，IP3或细胞内钙测量的信号转导途径连接的前列腺素F2α受体的分子克隆和表达。通过构建表达前列腺素F2α受体的细胞系，可以评估激动剂和拮抗剂药物与受体的亲和力和功效。重组DNA构建体包含载体和编码前列腺素F2α受体的DNA片段。用重组DNA构建体转化宿主细胞，使得DNA片段被表达并产生前列腺素F2α受体。合适的宿主系统包括真核细胞和原核细胞，特别是哺乳动物细胞如大鼠或人。此外，为了诊断目的，可以通过产生全部或部分受体蛋白并将它们注入各种类型的哺乳动物来制备对前列腺素F2α受体的抗体。使用得到的抗体，可以测量组织和细胞中的F2α受体cDNA，即受体蛋白的表达。

6. 发明申请

WO1994007510A1 COMPOSITION COMPRISING COAGULATION FACTOR VIII FORMULATION, PROCESS FOR ITS PREPARATION AND USE OF A SURFACTANT AS STABILIZER 审中-公开
标题翻译：包含凝血因子VIII的组合物配方，其制备和使用作为稳定剂的表面活性剂的方法
公开(公告)号：WO1994007510A1
公开(公告)日：1994-04-14
申请号：PCT/SE1993000793
申请日：1993-10-01
申请人： KABI PHARMACIA AB , ÖSTERBERG, Thomas , FATOUROS, Angelica
发明人： KABI PHARMACIA AB
IPC分类号： A61K35/16
CPC分类号： A61K47/183 , A61K9/0019 , A61K9/1075 , A61K9/19 , A61K38/37 , A61K47/02 , A61K47/26 , A61K47/42 , C07K14/755 , C12N9/96 , Y10S514/834 , Y10S530/83
摘要： The present invention relates to novel composition comprising coagulation factor VIII and a non-ionic surfactant such as block copolymers, e.g. polyoxamers or polyoxyethylene (20) sorbitan fatty acid esters e.g. polysorbate 20 or polysorbate 80 as stabilizer. The composition can also comprise sodium chloride, calcium chloride, L-histidine and/or sugars or sugar alcohols. The invention also relates to the use of a non-ionic surfactant as stabilizer for a composition comprising coagulation factor VIII.
摘要翻译：本发明涉及包含凝血因子VIII和非离子表面活性剂如嵌段共聚物的新型组合物，例如，聚氧乙烯或聚氧乙烯（20）脱水山梨糖醇脂肪酸酯，例如聚山梨醇酯20或聚山梨醇酯80作为稳定剂。组合物还可以包含氯化钠，氯化钙，L-组氨酸和/或糖或糖醇。本发明还涉及非离子表面活性剂作为包含凝血因子VIII的组合物的稳定剂的用途。

7. 发明申请

WO1993023071A1 USE OF IGF-1 审中-公开
标题翻译： IGF-1的使用
公开(公告)号：WO1993023071A1
公开(公告)日：1993-11-25
申请号：PCT/SE1993000425
申请日：1993-05-14
申请人： KABI PHARMACIA AB , DUNGER, David, B. , SAVAGE, Martin, O. , SÖNKSEN, Peter, H.
发明人： KABI PHARMACIA AB
IPC分类号： A61K37/36
CPC分类号： A61K38/30
摘要： The invention relates to the use of IGF-1 for the manufacture of a medicament for treatment of Type 1 diabetes mellitus, the medicament comprising a subcutaneous dose not greater than needed to achieve an IGF-1 serum level characteristic for healthy individuals i.e. a physiological replacement of serum IGF-1. This treatment would be especially valuable for the treatment of children or adolescents with Type 1 diabetes mellitus and could lead to improvements in their pubertal growth.
摘要翻译：本发明涉及IGF-1用于制备用于治疗1型糖尿病的药物的用途，所述药物包含不大于实现健康个体的IGF-1血清水平特征所需的皮下剂量，即生理替代的血清IGF-1。这种治疗对于治疗1型糖尿病的儿童或青少年尤其有价值，并可能导致其青春期生长的改善。

8. 发明申请

WO1993020869A1 INJECTION DEVICE 审中-公开
标题翻译：注射装置
公开(公告)号：WO1993020869A1
公开(公告)日：1993-10-28
申请号：PCT/SE1993000336
申请日：1993-04-16
申请人： KABI PHARMACIA AB , HJERTMAN, Birger , LEVANDER, Gustav , LJUNGQUIST, Olle
发明人： KABI PHARMACIA AB
IPC分类号： A61M05/31
CPC分类号： A61M5/284 , A61M5/31586 , A61M2005/3123 , A61M2205/6045 , F26B5/06
摘要： A device to be used in the filling and sealing of injection cartridges of the dual-chamber type comprises a cylindrical sleeve (7) which is arranged slidably around said cartridge, and a stopper (11) which is directed rearward and is coaxial with the sleeve and the cartridge. The sleeve (7) with the stopper (11) is arranged around the cartridge before the contents of the cartridge is subjected to a freeze-drying process, such that a vapor connection (16) exists between the interior of the cartridge and the exterior of the sleeve. After completed freeze-drying, the sleeve (7) and the stopper (11) are displaced rearwards, such that the stopper (11) enters the neck (2) of the cartridge and seals it. This is carried out before the cartridge has come into contact with atmospheric air. At its rear end, the sleeve (7) may be provided with an attachment (17) for a device for preparing and administering injections.
摘要翻译：用于双室型注射筒的填充和密封中的装置包括：圆筒形套筒（7），其围绕所述盒可滑动地布置;以及止动器（11），其向后指向并与套筒同轴和墨盒。具有止动器（11）的套筒（7）在盒的内容物进行冷冻干燥处理之前围绕盒子布置，使得在盒的内部和盒的内部之间存在蒸气连接（16）袖子。完成冷冻干燥后，套筒（7）和止动器（11）向后移位，使得止动器（11）进入盒的颈部（2）并将其密封。这是在墨盒与大气接触之前进行的。在其后端，套筒（7）可以设置有用于准备和管理注射的装置的附件（17）。

9. 发明申请

WO1993018753A1 PROCESS FOR THE PREPARATION OF SUSTAINED RELEASE PELLETS 审中-公开
标题翻译：制备持续释放小块的方法
公开(公告)号：WO1993018753A1
公开(公告)日：1993-09-30
申请号：PCT/SE1993000225
申请日：1993-03-16
申请人： KABI PHARMACIA AB , KRISTENSEN, Henning, G. , SCHAEFER, Torben , THOMSEN, Lars, Juul , KRISTENSEN, Arne
发明人： KABI PHARMACIA AB
IPC分类号： A61K09/16
CPC分类号： A61K9/1694 , A61K9/1611 , A61K9/1617
摘要： A process for the manufacture of sustained release pellets comprising pelletizing a mixture containing the drug in finely divided form and a binder. The characteristic feature is that: (a) said binder is in particle form consisting of one or more water-insoluble wax-like binder substance(s) with a melting point above 40 DEG C, and (b) said pelletization step is performed by mechanically working said mixture, in a high shear mixer, under the input of a sufficient amount of energy for the binder to melt and pelletization to take place.
摘要翻译：一种用于制造缓释丸的方法，包括将含有细碎形式的药物的混合物和粘合剂造粒。其特征在于：（a）所述粘合剂是由一种或多种熔点高于40℃的水不溶性蜡状粘合剂物质构成的颗粒形式，（b）所述造粒步骤由在高剪切混合器下，在足够量的能量的输入下机械加工所述混合物，以使粘合剂熔化和造粒发生。

10. 发明申请

WO1992022311A1 NEW MEDICINAL USE OF IGF-II 审中-公开
标题翻译： IGF-II的新药物使用
公开(公告)号：WO1992022311A1
公开(公告)日：1992-12-23
申请号：PCT/SE1992000397
申请日：1992-06-11
申请人： KABI PHARMACIA AB , LAKE, Mats , JENNISCHE, Eva
发明人： KABI PHARMACIA AB
IPC分类号： A61K37/02
CPC分类号： A61K38/30 , Y10S424/13 , Y10S514/921
摘要： The use of IGF-II for preparing a medicament for the regeneration of muscle tissue; and methods for medical treatment for the purpose of regenerating muscle tissue, for minimizing scar formation during healing of a wound or for preventing undesired tissue adhesion after injury, such as after surgery.
摘要翻译：使用IGF-II制备用于再生肌肉组织的药物; 以及用于再生肌肉组织的目的的医疗处理方法，用于使伤口愈合期间的瘢痕形成最小化或者用于防止在损伤后例如手术后不期望的组织粘连。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式